Healthcare systems are no longer navigating a temporary staffing disruption. They are operating within a sustained structural constraint defined by chronic nursing shortages, rising labor costs, and increasing accountability for outcomes across inpatient and outpatient settings. Clinical teams are being asked to do more with fewer available hours, while financial leaders face pressure to control costs without compromising quality or safety.
At the center of this challenge is a workflow that has changed little in decades. Manual vital sign collection remains a foundational task across healthcare settings, even as patient acuity rises and staffing availability declines. Nurses spend up to and sometimes in excess of 20% of their shifts measuring and documenting vitals, often on fixed schedules that provide only intermittent insight into patient condition. This model consumes scarce labor while still leaving gaps in clinical visibility.
Senphonix was created to address this problem directly. The SleeveSense platform automates vital sign collection and delivers continuous physiological data without adding tasks, devices to manage, or workflows to supervise. Monitoring happens in the background, without requiring patient interaction or clinician intervention. The result is not simply more data but recovered nursing time and earlier clinical insight.
Research conducted by MarketWise Advising reinforces the urgency of this approach. In a nationwide study of 402 nurses (2025), 98% indicated they saw clear value in automated, continuous monitoring and stated they would support adoption of SleeveSense within their healthcare organization. Nurses consistently emphasized that automation, not incremental efficiency, is what makes adoption viable in an already overburdened environment.
“Manual vitals are not the best use of a nurse’s time anymore. If a system can collect them automatically and reliably, that time goes straight back to patient care, where it belongs.”
"There’s too much that happens between vitals. This would help us intervene earlier."
Financial leaders reached similar conclusions. In a separate national study of 457 financial leaders (2026), the overwhelming majority of finance executives in healthcare identified labor recovery as the most compelling driver of value for SleeveSense, followed closely by readmission avoidance and the ability to support reimbursable remote patient monitoring without capital investment. These leaders were not evaluating technology as a discretionary upgrade; they were evaluating it as infrastructure necessary to sustain operations.
Senphonix delivers automated monitoring designed to operate invisibly across inpatient and outpatient settings, restoring clinical capacity, reducing reliance on premium labor, and improving visibility across the full episode of care.
Senphonix is more than a medical device company. We’re a partner in creating the future of intelligent, compassionate care, where healthcare systems run more efficiently, nursing teams feel more supported, and patients stay healthier.
“We are not looking for technology that adds capability. We are looking for technology that gives us capacity back. That distinction matters.”
SleeveSense™ will be available upon FDA clearance, which is expected in early 2027.
Senphonix is a Delaware C-corp., with offices in Minnesota and Arizona. For more information, contact us at info@senphonix.com or 612-913-0607; or follow us on LinkedIn. Copyright © 2026 Senphonix, Inc. - All Rights Reserved. Logos and trademarks are the property of their respective owners. All quotes herein are drawn from anonymous responses to two MarketWise Advising ("MarketWise") national studies, commissioned by Senphonix; some quotes were lightly edited for brevity.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.